Loading clinical trials...
Loading clinical trials...
A PHASE III, RANDOMISED, OPEN, CONTROLLED, MULTICENTRE, PRIMARY VACCINATION STUDY TO EVALUATE THE IMMUNOGENICITY AND PERSISTENCE OF 1 AND 2 DOSES OF MENINGOCOCCAL CONJUGATE VACCINE MENACWY-TT IN TODDLERS (AFTER 1 MONTH AND UP TO 5 YEARS) AND TO DEMONSTRATE NON-INFERIORITY OF CO-ADMINISTRATION OF MENACWY-TT AND 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE PREVENAR 13(REGISTERED) VERSUS SEPARATE ADMINISTRATION OF THE 2 VACCINES
Conditions
Interventions
Meningococcal vaccine GSK134612
Prevenar 13™
Locations
51
Australia
Canberra Hospital
Garran, Australian Capital Territory, Australia
The Childrens Hospital at Westmead
Westmead, New South Wales, Australia
Women's and Children's Hospital
North Adelaide, South Australia, Australia
Vaccine and Immunization Research Group
Melbourne, Victoria, Australia
Vaccine Trials Group, Telethon Kids Institute, Perth Children's Hospital
Nedlands, Western Australia, Australia
The Clinical Research Unit; Children's Hospital Research Institute of Manitoba [CHRIM]
Winnipeg, Manitoba, Canada
Start Date
October 2, 2013
Primary Completion Date
December 5, 2019
Completion Date
December 5, 2019
Last Updated
October 5, 2021
NCT04886154
NCT01266993
NCT02451514
NCT02946385
NCT02639351
NCT01900899
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions